

Alzheimer's Disease (AD)

An Open-Label Crenezumab Study in Patients With Alzheimer's Disease

Trial Status
Terminated

Trial Runs In
17 Countries

Trial Identifier
NCT03491150 2017-002702-12
BN40031

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg intravenous (IV) every 4 weeks (Q4W) will be offered to all participants who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in participants on long-term crenezumab treatment and to investigate the effect of crenezumab on the underlying disease process and disease course as an exploratory efficacy objective.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03491150 2017-002702-12 BN40031
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
All

Healthy Volunteers
No
